Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells

Nature Protocols

Volumn 5, Issue 6, 2010, Pages 1081-1095

  Rosner, Margit ^a   Siegel, Nicol ^a   Fuchs, Christiane ^a   Slabina, Nina ^a   Dolznig, Helmut ^a   Hengstschläger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA;

AMNION FLUID; ARTICLE; CYTOLOGY; EMBRYONIC STEM CELL; FEMALE; GENE SILENCING; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; HUMAN; IN VITRO STUDY; METABOLISM; METHODOLOGY; PREGNANCY; RNA INTERFERENCE;

AMNIOTIC FLUID; EMBRYONIC STEM CELLS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENETIC ENGINEERING; HUMANS; PREGNANCY; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77955400436     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2010.74     Document Type: Article

References (30)

1. Prusa, A.R., Marton, E., Rosner, M., Bernaschek, G. & Hengstschläger, M. Oct4 expressing cells in human amniotic fluid: a new source for stem cell research? Hum. Reprod. 18, 1489-1493 (2003).
2. De Coppi, P. et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotech. 25, 100-106 (2007).
3. Valli, A. et al. Embryoid body formation of human amniotic fluid stem cells depends on mTOR. Oncogene 29, 966-977 (2010).
4. Siegel, N., Rosner, M., Hanneder, M., Valli, A. & Hengstschläger, M. Stem cells in amniotic fluid as new tools to study human genetic diseases. Stem. Cell Rev. 3, 256-264 (2007).
5. Perin, L., Sedrakyan, S., Da Sacco, S. & De Filippo, R. Characterization of human amniotic fluid stem cells and their pluripotential capability. Methods Cell Biol. 86, 85-99 (2008).
6. Cananzi, M., Atala, A. & DeCoppi, P. Stem cells derived from amniotic fluid: new potentials in regenerative medicine. Reprod. Biomed. Online 18,17-27 (2009).
7. Pappa, K. & Anagnou, N.P. Novel sources of fetal stem cells: where do they fit on the developmental continuum? Regen. Med. 4, 423-433 (2009).
8. Whitehead, K.A., Langer, R. & Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. 8, 129-138 (2009).
9. Schaniel, C. et al. Delivery of short hairpin RNAs-triggers of gene silencing-into mouse embryonic stem cells. Nat. Methods 3, 397-400 (2006).
10. Hough, S.R., Clements, I., Welch, P.J. & Wiederholt, K.A. Differentiation of mouse embryonic stem cells after RNA interference-mediated silencing of Oct4 and Nanog. Stem Cells 24, 1467-1475 (2006).
11. Karlmark, K.R. et al. Activation of ectopic Oct4 and Rex-1 promoters in human amniotic fluid cells. Int. J. Mol. Med. 16, 987-992 (2005).
12. Grisafi, D. et al. High transduction efficiency of human amniotic fluid stem cells mediated by adenovirus vectors. Stem Cell Dev. 17, 953-962 (2008).
13. Ye, L. et al. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc. Natl Acad. Sci. USA 106, 9826-9830 (2009).
14. Li, C. et al. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum. Mol. Genet. 18, 4340-4349 (2009).
15. Cheng, F.C. et al. Enhancement of regeneration with glia cell linederived neurotrophic factor-transduced human amniotic fluid mesenchymal stem cells after sciatic nerve crush injury. J. Neurosurg 112, 868-879 (2010).
16. Rosner, M. et al. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis? Eur. J. Clin. Invest. 39, 1033-1035 (2009).
17. Chu, I.M., Hengst, L. & Slingerland, J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8, 253-267 (2008).
18. Rosner, M. et al. The mTOR pathway and its role in human genetic diseases. Mutat. Res. 659, 284-292 (2008).
19. Wang, X. & Proud, C.G. Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol. 19, 260-267 (2009).
20. Rosner, M., Fuchs, C., Siegel, N., Valli, A. & Hengstschläger, M. Functional interaction of mTOR complexes in regulating mammalian cell size and cell cycle. Hum. Mol. Genet. 18, 3298-3310 (2009).
21. Dunlop, E.A. & Tee, A. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal. 21, 827-835 (2008).
22. Karni, R. et al. The gene encoding the splicing factor SF2/ASF is a protooncogene. Nat. Struct. Mol. Biol. 14, 185-193 (2007).
23. Li, X. & Manley, J.L. Alternative splicing and control of apoptotic DNA fragmentation. Cell Cycle 5, 1286-1288 (2006).
24. Rosner, M., Hanneder, M., Siegel, N., Valli, A. & Hengstschläger, M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat. Res. 658, 234-246 (2008).
25. Siegel, N., Valli, A., Fuchs, C., Rosner, M. & Hengstschläger, M. Induction of mesenchymal/epithelial marker expression in human amniotic fluid stem cells. Reprod. Biomed. Online 19, 838-846 (2009).
26. Rosner, M. et al. p27Kip1 localization depends on the tumor suppressor protein tuberin. Hum. Mol. Genet. 16, 1541-1556 (2007).
27. Kalejta, R.F., Shenk, T. & Beavis, A.J. Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. Cytometry 29, 286-291 (2007).
28. Omi, K., Tokunaga, K. & Hohjoh, H. Long-lasting RNAi activity in mammalian neurons. FEBS Lett. 558, 89-95 (2004).
29. Vandenbroucke, R.E. et al. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly (ß-amino esters). J. Gene Med. 10, 783-794 (2008).
30. Mantei, A. et al. siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur. J. Immunol. 38, 2616-2625 (2008).